[Anti-CD19-liposomes encapsulated domain III of pseudomonas exotoxin in the targeting of human B lymphoma].
To evaluate the targeting ability and cytotoxicity of domain III of pseudomonas exotoxin encapsulated in anti-CD19-immunoliposomes to lymphoma cells in vitro and in vivo. Binding ability of anti-CD19 immunoliposomes to B lymphoma cells was detected by binding assay. MTT assay was used to detect the cytotoxicity of free domain III and domain III encapsulated in anti-CD19-immunoliposomes against B lymphoma cells. An in vivo therapeutic study of domain III formulated in immunoliposomes on human B lymphoma was detected in a murine model. The cytotoxicity of free domain III disappeared when domain I and II were deleted. When domain III was encapsulated into anti-CD19-immunoliposomes, the cytotoxicity of immunoliposomes against tumor cells were significantly increased. Treatment, using this formulation, of mice inoculated with B lymphoma could enhance the survival time. Anti-CD19-immunoliposomes, as drug carriers, can specifically recognize B lymphoma cells and deliver non-toxic domain III into the tumor cells. This formulation of domain III might be an effective anti-tumor agent.